Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an update.
Shanghai Fosun Pharmaceutical has announced the proposed adoption of the 2025 H Share RSU Scheme, aimed at enhancing corporate governance and establishing a long-term incentive mechanism. The scheme, which requires shareholder approval, includes a first grant of 10,696,400 RSUs to 201 eligible employees, aligning the interests of shareholders and key personnel to drive the company’s long-term development.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, operating in the pharmaceutical industry. The company focuses on developing, manufacturing, and selling pharmaceutical products and medical devices, with a market focus on both domestic and international sectors.
YTD Price Performance: 49.18%
Average Trading Volume: 10,777,457
Technical Sentiment Signal: Hold
Current Market Cap: HK$76.06B
See more insights into 2196 stock on TipRanks’ Stock Analysis page.